Adnexal masses and malignancies of importance to the colorectal surgeon

In this article, the authors review both benign and malignant ovarian masses, as the colorectal surgeon who encounters an adnexal mass at the time of surgery should be aware of the steps necessary for surgical staging and optimal tumor resection. Ovarian tumors—most of which are benign—are divided into three major categories, in order of frequency: epithelial, germ cell, and sex cord-stromal tumors. Nonneoplastic conditions of the ovary that may present as adnexal masses include the following, according to World Health Organization (WHO) classification: pregnancy luteoma, hyperplasia of ovarian stroma, hyperthecosis, massive edema, solitary follicle cysts and corpus luteal cysts, multiple follicle cysts, and endometriosis. Epithelial ovarian tumors arise from the surface epithelium and can be benign or malignant. Histologic types are serous, mucinous, endometrioid, clear cell, or Brenner. Germ cell tumors are more likely to appear in females under 20 years, accounting for 70% of ovarian tumors in this age group. Approximately 3% are malignant. Teratomas are the most common germ cell tumors. Malignancies, in addition to malignant teratomas, include dysgerminomas, endodermal sinus tumors, and embryonal carcinomas. The more common sex cord-stromal tumors include granulosa stromal cell tumors, Sertoli–Leydig cell tumors, and gynandroblastomas. Surgical staging and optimal tumor resection are also addressed, with a focus on epithelial malignancies, as they are the most relevant to colorectal surgeons.

Adnexal masses - ovarian cancer - ovarian cysts

- 1 Scully R E. Classification of human ovarian tumors. Environ Health Perspect. 1987; 73 15-25 - 2 Berek J S, Hacker N F. Nonepithelial ovarian and fallopian tube cancers . In: Berek JS, Hacker NF Practical Gynecologic Oncology. Philadelphia; Lippincott Williams & Wilkins 2005: 511-541 - 3 Partridge E, Kreimer A R, Greenlee R T PLCO Project Team et al. Results from four rounds of ovarian cancer screening in a randomized trial. Obstet Gynecol. 2009; 113(4) 775-782 - 4 van Nagell J R, DePriest P D. Management of adnexal masses in postmenopausal women. Am J Obstet Gynecol. 2005; 193(1) 30-35 - 5 Granberg S, Wikland M, Jansson I. Macroscopic characterization of ovarian tumors and the relation to the histological diagnosis: criteria to be used for ultrasound evaluation. Gynecol Oncol. 1989; 35(2) 139-144 - 6 Stenchever M A, Droegemueller W, Herbst A L. Mishell Dr. Comprehensive Gynecology. Maryland Heights, MO; Mosby 2001 - 7 Koonings P P, Campbell K, Mishell Jr D R, Grimes D A. Relative frequency of primary ovarian neoplasms: a 10-year review. Obstet Gynecol. 1989; 74(6) 921-926 - 8 Scully R E, Young R H, Clement P B. Tumors of the ovary, maldeveloped gonads, fallopian tube, and broad ligament . In: Scully RE, Young RH, Clement PB Atlas of Tumor Pathology, Third Series, Fascicle 23. Washington, DC; Armed Forces Institute of Pathology 1998: 27-50 - 9 Berek J S. Epithelial ovarian cancer . In: Berek JS, Hacker NF Practical Gynecologic Oncology. Philadelphia; Lippincott Williams & Wilkins 2005: 443-509 - 10 Silverberg S G. Prognostic significance of pathologic features of ovarian carcinoma. Curr Top Pathol. 1989; 78 85-109 - 11 Ludescher C, Weger A R, Lindholm J et al.. Prognostic significance of tumor cell morphometry, histopathology, and clinical parameters in advanced ovarian carcinoma. Int J Gynecol Pathol. 1990; 9(4) 343-351 - 12 Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun M J. Cancer statistics, 2009. CA Cancer J Clin. 2009; 59(4) 225-249 - 13 Kosary C L. Cancer of the ovary. In: SEER Survival Monograph: Cancer Survival Among Adults: US SEER Program, 1988–2001, Patient and Tumor Characteristics [T-098] Pub. No. 07–6215. Bethesda, MD: National Cancer Institute; 2002:133–144. Available at: http://Seer.cancer.gov/publications/survival/surv_ovary.pdf Accessed January 31, 2010 - 14 Tinelli R, Tinelli A, Tinelli F G, Cicinelli E, Malvasi A. Conservative surgery for borderline ovarian tumors: a review. Gynecol Oncol. 2006; 100(1) 185-191 - 15 Trimble C L, Kosary C, Trimble E L. Long-term survival and patterns of care in women with ovarian tumors of low malignant potential. Gynecol Oncol. 2002; 86(1) 34-37 - 16 Chen L, Berek J S. Ovarian tumors of low malignant potential . In: Basow DS UpToDate. Waltham, MA; UpToDate 2009 - 17 Scully R E, Young R H, Clement P B. Tumors of the ovary, maldeveloped gonads, fallopian tube, and broad ligament . In: Scully RE, Young RH, Clement PB Atlas of Tumor Pathology, Third Series, Fascicle 23. Washington DC; Armed Forces Institute of Pathology 1998: 239-266 - 18 Williams S D, Gershenson D M, Horowitz C J, Silva E. Ovarian germ-cell tumors . In: Hoskins WJ, Perez CA, Young RJ Principles and Practice of Gynecologic Oncology. Philadelphia; Lippincott Williams & Wilkins 2000: 1059-1073 - 19 Goff B A, Matthews B J, Wynn M, Muntz H G, Lishner D M, Baldwin L M. Ovarian cancer: patterns of surgical care across the United States. Gynecol Oncol. 2006; 103(2) 383-390 - 20 Young R C, Decker D G, Wharton J T et al.. Staging laparotomy in early ovarian cancer. JAMA. 1983; 250(22) 3072-3076 - 21 Hacker N F, Berek J S, Lagasse L D, Nieberg R K, Elashoff R M. Primary cytoreductive surgery for epithelial ovarian cancer. Obstet Gynecol. 1983; 61(4) 413-420 - 22 Piver M S, Lele S B, Marchetti D L, Baker T R, Tsukada Y, Emrich L J. The impact of aggressive debulking surgery and cisplatin-based chemotherapy on progression-free survival in stage III and IV ovarian carcinoma. J Clin Oncol. 1988; 6(6) 983-989 - 23 Armstrong D K, Bundy B, Wenzel L Gynecologic Oncology Group et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006; 354(1) 34-43 - 24 Makhija S, Leitao M, Sabbatini P et al.. Complications associated with intraperitoneal chemotherapy catheters. Gynecol Oncol. 2001; 81(1) 77-81 Richard C KlineM.D. Department of Obstetrics and Gynecology, Ochsner Clinic Foundation 1514 Jefferson Hwy., New Orleans, LA 70121 Email: [email protected]